Identifies multi-target antidepressant candidates using computational screening in drug development, suggesting new treatment options.
Major depressive disorder (MDD) treatment is limited by high rates of incomplete symptom remission, necessitating polypharmacological approaches. This study executes a hierarchical in silico workflow as a strictly predictive, hypothesis-generating stage to identify putative multi-target antidepressant candidates. A ligand-based similarity screen of the ZINC database generated an initial library of 14,561 analogs based on the structural templates of established antidepressant drugs. This dataset was subjected to multi-stage computational filtering integrating quantitative structure-activity relationship (QSAR) modeling, molecular docking, and predictive ADMET profiling. The pipeline prioritized 298 compounds that demonstrate in silico binding scores potentially higher to their respective parent reference drugs across a panel of monoaminergic transporters, serotonergic receptors, and glutamatergic targets. These prioritized analogs exhibit computationally optimized multi-target profiles, maintaining predicted blood-brain barrier permeability while reducing in silico liabilities for hERG channel inhibition and hepatotoxicity.
No takes yet. Share an insight, caveat, or question.
Höfs et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: